AG 126

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

酪氨酸磷酸化抑制剂 AG-126 在 25-50 μM 时选择性抑制 ERK1 (p44) 和 ERK2 (p42) 的磷酸化。

AG 126 selectively inhibits the phosphorylation. It also acts as a cell-permeable inhibitor of lipopolysaccharide (LPS)-induced synthesis of tumor necrosis factor-α and nitric oxide in murine peritoneal macrophages.

AG126 (10 μM; overnight) increases the viability of ARPE-19 cells.AG126 at concentrations higher than 10 μM show toxic to ARPE-19 cells and can enhance H2O2 toxicity.AG126 (0.1-100 μM) inhibits VEGF-induced proliferation of BRMECs. Cell Viability Assay Cell Line:ARPE-19 cells Concentration:10 μM Incubation Time:Overnight Result:Increased the viability of ARPE-19 cells to 35-72% compared to the control.Cell Proliferation Assay Cell Line:BRMECs Concentration:0.1-100 μM Incubation Time:Result:Inhibited VEGF-induced proliferation of BRMECs in a dose-dependent manner.

AG 126 (intraperitoneal injection; 1-10 mg/kg; 1 h and 6 h after Zymosan treatment) treatment attenuates the degree of multiple organ failure (MOF) associated with Zymosan-induced peritonitis in the rat. Animal Model:Male Sprague-Dawley rats treated with Zymosan (500 mg/kg)Dosage:10 mg/kg, 3 mg/kg or 1 mg/kg Administration:Intraperitoneal injection; 10, 3, or 1 mg/kg; 1 h and 6 h after Zymosan treatment Result:Attenuated the peritoneal exudation and the migration of polymorphonuclear cells caused by Zymosan in a dose-dependent fashion.Attenuated the lung, liver, and intestinal injury.Reduced the production of peroxynitrite and of pro-inflammatory cytokines TNF-alpha and IL-1beta.

AG 126 | Tyrphostin AG 126 | UNII-7YA4AMD1JC

Cytoskeleton/Cell Adhesion Molecules

Akt

COX-2| ERK1,2

Inflammation/Immunology

——

118409-62-4

215.17

C10H5N3O3

>98% (HPLC)

DMSO : 100 mg/mL. 464.75 mM;

C1=CC(=C(C=C1C=C(C#N)C#N)O)[N+](=O)[O-]

Propanedinitrile, ((3-hydroxy-4-nitrophenyl)methylene)-

(-20℃)

With Ice Pack

≥ 2 years